AR031383A1 - Metodo de dosificacion in vitro de la fibrina soluble por generacion de productos de degradacion especificos, un testigo positivo utilizable en dicho metodo, utilizacion de un activador de plasminogeno de fuerte afinidad para un metodo de dosificacion de la fibrina soluble, un equipo de dosificacion - Google Patents
Metodo de dosificacion in vitro de la fibrina soluble por generacion de productos de degradacion especificos, un testigo positivo utilizable en dicho metodo, utilizacion de un activador de plasminogeno de fuerte afinidad para un metodo de dosificacion de la fibrina soluble, un equipo de dosificacionInfo
- Publication number
- AR031383A1 AR031383A1 ARP010103515A ARP010103515A AR031383A1 AR 031383 A1 AR031383 A1 AR 031383A1 AR P010103515 A ARP010103515 A AR P010103515A AR P010103515 A ARP010103515 A AR P010103515A AR 031383 A1 AR031383 A1 AR 031383A1
- Authority
- AR
- Argentina
- Prior art keywords
- soluble
- fibrine
- degradation products
- fibrin
- generation
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 7
- 102000001938 Plasminogen Activators Human genes 0.000 title abstract 2
- 108010001014 Plasminogen Activators Proteins 0.000 title abstract 2
- 239000007857 degradation product Substances 0.000 title abstract 2
- 229940127126 plasminogen activator Drugs 0.000 title abstract 2
- 238000000338 in vitro Methods 0.000 title 1
- 108010073385 Fibrin Proteins 0.000 abstract 7
- 102000009123 Fibrin Human genes 0.000 abstract 7
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 abstract 7
- 229950003499 fibrin Drugs 0.000 abstract 7
- 108010058861 Fibrin Fibrinogen Degradation Products Proteins 0.000 abstract 2
- 239000000208 fibrin degradation product Substances 0.000 abstract 2
- 238000001994 activation Methods 0.000 abstract 1
- 239000012190 activator Substances 0.000 abstract 1
- 239000003146 anticoagulant agent Substances 0.000 abstract 1
- 229940127219 anticoagulant drug Drugs 0.000 abstract 1
- 230000015556 catabolic process Effects 0.000 abstract 1
- 230000015271 coagulation Effects 0.000 abstract 1
- 238000005345 coagulation Methods 0.000 abstract 1
- 238000006731 degradation reaction Methods 0.000 abstract 1
- 239000013641 positive control Substances 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/56—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving blood clotting factors, e.g. involving thrombin, thromboplastin, fibrinogen
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Biophysics (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Un método de dosificacion de la fibrina soluble en una muestra, en la cual se coloca dicha muestra en presencia de un activador del plasminogeno de fuerte especifidad para la fibrina soluble (PA-Fb sp) y se mide el tenor de la muestra de fibrina soluble, midiendo la diferencia entre la tasa de productos de degradacion de la fibrina obtenidos después de la degradacion de la fibrina soluble por el PA-Fb sp y la tasa de base de los productos de degradacion de la fibrina, determinados sobre dicha muestra antes de poner la misma en presencia del PA-Fb sp; un testigo positivo utilizable en dicho método; utilizacion de un activador de plaminogeno de fuerte afinidad para la fibrina en un método de dosificacion de la fibrina soluble por generacion de productos de degradacion específicos; un equipo de dosificacion de la fibrina soluble y utilizacion de método o del equipo para seguir la evolucion de un proceso de activacion de la coagulacion y evaluar la eficacia de una terapéutica anti-coagulante.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0010999A FR2813395B1 (fr) | 2000-08-28 | 2000-08-28 | Methode de dosage in vitro de la fibrine soluble par generation de produits de degradation specifiques |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR031383A1 true AR031383A1 (es) | 2003-09-24 |
Family
ID=8853768
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP010103515A AR031383A1 (es) | 2000-08-28 | 2001-07-23 | Metodo de dosificacion in vitro de la fibrina soluble por generacion de productos de degradacion especificos, un testigo positivo utilizable en dicho metodo, utilizacion de un activador de plasminogeno de fuerte afinidad para un metodo de dosificacion de la fibrina soluble, un equipo de dosificacion |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US8883433B2 (es) |
| EP (1) | EP1313877B1 (es) |
| JP (1) | JP5049448B2 (es) |
| KR (1) | KR20030051630A (es) |
| CN (2) | CN102445546A (es) |
| AR (1) | AR031383A1 (es) |
| AT (1) | ATE453724T1 (es) |
| AU (2) | AU2001284147B2 (es) |
| BR (1) | BR0113558A (es) |
| CA (1) | CA2420617A1 (es) |
| CZ (2) | CZ2003600A3 (es) |
| DE (1) | DE60140948D1 (es) |
| ES (1) | ES2337879T3 (es) |
| FR (1) | FR2813395B1 (es) |
| HU (1) | HUP0500620A2 (es) |
| MX (1) | MXPA03001841A (es) |
| PL (1) | PL361139A1 (es) |
| RU (1) | RU2310200C2 (es) |
| WO (1) | WO2002018628A1 (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2813395B1 (fr) | 2000-08-28 | 2003-01-24 | Stago Diagnostica | Methode de dosage in vitro de la fibrine soluble par generation de produits de degradation specifiques |
| FR2900734B1 (fr) | 2006-05-05 | 2009-03-06 | Diagnostica Stago Soc Par Acti | Detection des maladies veineuses thromboemboliques par le dosage des d-dimeres et de la fibrine soluble |
| FR2948666A1 (fr) | 2009-07-30 | 2011-02-04 | Univ Paris Curie | Methode de diagnostic d'un cancer et de determination de la severite d'un cancer chez un individu |
| JP5984670B2 (ja) * | 2010-07-30 | 2016-09-06 | シスメックス株式会社 | Ｆｄｐ測定用試薬及び試薬キット、並びに測定方法 |
| CN104458367B (zh) * | 2014-11-06 | 2019-03-26 | 上海长岛生物技术有限公司 | 一种d-二聚体和fdp复合质控品及其制备方法 |
| CN104459103B (zh) * | 2014-12-15 | 2016-04-27 | 中国医学科学院输血研究所 | D-二聚体质控品的制备方法 |
| BR112018017170A2 (pt) * | 2016-02-22 | 2019-01-02 | Lsi Medience Corp | reagente de medição para o produto de degradação de fibrina reticulada, e método de medição |
| US10793327B2 (en) | 2017-10-09 | 2020-10-06 | Terumo Bct Biotechnologies, Llc | Lyophilization container and method of using same |
| EP3938741B1 (en) | 2019-03-14 | 2024-05-01 | Terumo BCT Biotechnologies, LLC | Lyophilization container fill fixture, system and method of use |
| RU2703541C1 (ru) * | 2019-03-15 | 2019-10-21 | федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр профилактической медицины" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ ПМ" Минздрава России) | Способ определения фибриногена при рекальцификации цитратной плазмы и оценка его функциональности |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SU1354115A1 (ru) * | 1985-03-22 | 1987-11-23 | Институт биохимии им.А.В.Палладина | Способ определени содержани растворимого фибрина в плазме крови |
| SE447579B (sv) * | 1985-04-01 | 1986-11-24 | Biopool Ab | Solubiliserbar, fibrinbaserad komposition och anvendning av kompositionen vid bestemning av fibrinolysparametrar |
| US5114845A (en) * | 1987-07-06 | 1992-05-19 | Biopool International, Inc. | Assays for plasminogen activator inhibitor and soluble fibrin |
| US5175087A (en) * | 1987-07-06 | 1992-12-29 | Biopool International, Inc. | Method of performing tissue plasminogen activator assay |
| CA1324748C (en) * | 1987-07-06 | 1993-11-30 | Mats Gustaf Ranby | Assays for t-plasminogen activator and plasminogen activator inhibitor |
| DE3730059A1 (de) * | 1987-09-08 | 1989-03-30 | Behringwerke Ag | Verfahren zur bestimmung von "loeslichem" fibrin |
| US5453359A (en) * | 1988-06-13 | 1995-09-26 | American Biogenetic Sciences, Inc. | Immunoassay and kit for in vitro detection of soluble DesAABB fibrin polymers |
| US5206140A (en) * | 1988-06-24 | 1993-04-27 | Research Corporation Technologies, Inc. | Assay for soluble crosslinked fibrin polymers |
| IE67430B1 (en) * | 1988-06-24 | 1996-04-03 | Res Corp Technologies Inc | Assay for soluble crosslinked fibrin polymers |
| US5041376A (en) * | 1988-12-09 | 1991-08-20 | The Board Of Regents Of The University Of Texas System | Method for identifying or shielding functional sites or epitopes of proteins that enter the exocytotic pathway of eukaryotic cells, the mutant proteins so produced and genes encoding said mutant proteins |
| EP0678524B1 (en) * | 1993-11-02 | 2008-02-06 | Mitsubishi Kagaku Iatron, Inc. | Anti-human soluble fibrin antibodies, hybridoma producing them, and immunoassaying method |
| CA2266341A1 (en) * | 1996-09-20 | 1998-03-26 | The General Hospital Corporation | Composition and method for enhancing fibrinolysis using antibodies to alpha-2-antiplasmin |
| JP3472138B2 (ja) * | 1998-06-02 | 2003-12-02 | 帝国臓器製薬株式会社 | モノクローナル抗体及びｆｄｐの測定方法 |
| FR2813395B1 (fr) | 2000-08-28 | 2003-01-24 | Stago Diagnostica | Methode de dosage in vitro de la fibrine soluble par generation de produits de degradation specifiques |
| FR2900734B1 (fr) * | 2006-05-05 | 2009-03-06 | Diagnostica Stago Soc Par Acti | Detection des maladies veineuses thromboemboliques par le dosage des d-dimeres et de la fibrine soluble |
-
2000
- 2000-08-28 FR FR0010999A patent/FR2813395B1/fr not_active Expired - Lifetime
-
2001
- 2001-07-23 AR ARP010103515A patent/AR031383A1/es not_active Application Discontinuation
- 2001-08-17 AT AT01963106T patent/ATE453724T1/de not_active IP Right Cessation
- 2001-08-17 CN CN2011102910027A patent/CN102445546A/zh active Pending
- 2001-08-17 JP JP2002522534A patent/JP5049448B2/ja not_active Expired - Fee Related
- 2001-08-17 CA CA002420617A patent/CA2420617A1/en not_active Abandoned
- 2001-08-17 KR KR10-2003-7002841A patent/KR20030051630A/ko not_active Ceased
- 2001-08-17 MX MXPA03001841A patent/MXPA03001841A/es not_active Application Discontinuation
- 2001-08-17 AU AU2001284147A patent/AU2001284147B2/en not_active Ceased
- 2001-08-17 BR BR0113558-9A patent/BR0113558A/pt not_active IP Right Cessation
- 2001-08-17 AU AU8414701A patent/AU8414701A/xx active Pending
- 2001-08-17 DE DE60140948T patent/DE60140948D1/de not_active Expired - Lifetime
- 2001-08-17 HU HU0500620A patent/HUP0500620A2/hu unknown
- 2001-08-17 RU RU2003108504/15A patent/RU2310200C2/ru not_active IP Right Cessation
- 2001-08-17 WO PCT/FR2001/002628 patent/WO2002018628A1/fr not_active Ceased
- 2001-08-17 ES ES01963106T patent/ES2337879T3/es not_active Expired - Lifetime
- 2001-08-17 EP EP01963106A patent/EP1313877B1/fr not_active Expired - Lifetime
- 2001-08-17 CZ CZ2003600A patent/CZ2003600A3/cs unknown
- 2001-08-17 CN CN01815715A patent/CN1458980A/zh active Pending
- 2001-08-17 PL PL36113901A patent/PL361139A1/xx not_active Application Discontinuation
- 2001-08-28 CZ CZ20013111A patent/CZ20013111A3/cs unknown
-
2003
- 2003-02-25 US US10/373,614 patent/US8883433B2/en not_active Expired - Fee Related
-
2011
- 2011-09-23 US US13/242,996 patent/US9081024B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN1458980A (zh) | 2003-11-26 |
| US9081024B2 (en) | 2015-07-14 |
| US8883433B2 (en) | 2014-11-11 |
| US20120070855A1 (en) | 2012-03-22 |
| CN102445546A (zh) | 2012-05-09 |
| FR2813395B1 (fr) | 2003-01-24 |
| CZ2003600A3 (cs) | 2003-10-15 |
| MXPA03001841A (es) | 2004-11-01 |
| CZ20013111A3 (cs) | 2002-04-17 |
| US20030175839A1 (en) | 2003-09-18 |
| EP1313877B1 (fr) | 2009-12-30 |
| ES2337879T3 (es) | 2010-04-30 |
| RU2310200C2 (ru) | 2007-11-10 |
| KR20030051630A (ko) | 2003-06-25 |
| CA2420617A1 (en) | 2002-03-07 |
| WO2002018628A1 (fr) | 2002-03-07 |
| HUP0500620A2 (hu) | 2005-09-28 |
| BR0113558A (pt) | 2003-08-05 |
| AU8414701A (en) | 2002-03-13 |
| DE60140948D1 (de) | 2010-02-11 |
| AU2001284147B2 (en) | 2007-05-17 |
| FR2813395A1 (fr) | 2002-03-01 |
| ATE453724T1 (de) | 2010-01-15 |
| JP5049448B2 (ja) | 2012-10-17 |
| JP2004507745A (ja) | 2004-03-11 |
| EP1313877A1 (fr) | 2003-05-28 |
| PL361139A1 (en) | 2004-09-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR031383A1 (es) | Metodo de dosificacion in vitro de la fibrina soluble por generacion de productos de degradacion especificos, un testigo positivo utilizable en dicho metodo, utilizacion de un activador de plasminogeno de fuerte afinidad para un metodo de dosificacion de la fibrina soluble, un equipo de dosificacion | |
| AR057419A1 (es) | Dispositivo y metodo para rapidamente determinar la efectividad del procedimiento de esterilizacion o desinfeccion | |
| BR9914648A (pt) | Processo para monitorar ação medicamentosa deinibidor de proteasoma | |
| CY1116890T1 (el) | Πρωτοκολλο για παρακολουθηση αναστολης αιμοπεταλιου | |
| IS7764A (is) | Glútamín-þíasólidíð og -pýrrólidíð og notkun þeirra sem dípeptidýlpeptíðasa IV hindrar | |
| EP1585963A4 (en) | METHOD FOR EVALUATING A MYELOUS SUPPRESSION STATE | |
| EA200400966A1 (ru) | Новые лекарственные формы замещенного бензимидазола и способ их применения | |
| AR060857A1 (es) | Deteccion de enfermedades venosas tromboembolicas por la dosificacion de los d-dimeros y de la fibrina soluble | |
| BRPI0410467A (pt) | composições e métodos para tratamento de sìndrome respiratória aguda severa (sars) | |
| BRPI0406652A (pt) | Dispositivo refrescante de ar | |
| NO20025811L (no) | Forbindelser som er effektive som beta-2-adrenoreseptor- agonister så vel som PDE4-inhibitorer | |
| ATE448808T1 (de) | Hämostatische garnitur, verfahren zum zubereiten eines hämostatischen mittels und verfahren zur blutstillung | |
| AR048050A1 (es) | Formas de administracion masticables, no comprimidas, dosificadas individualmente | |
| BR112023023743A2 (pt) | Técnicas para relatório de medição de feixe | |
| AR037870A1 (es) | Metodo para determinar la actividad biologica de defibrotida | |
| MX169931B (es) | Procedimiento para determinar la catividad de serinproteasas inhibidores de serinproteasas | |
| EA200301271A1 (ru) | Способ диагностики или прогнозирования основных респираторных бактериальных патогенов у субъекта | |
| EP1362601A4 (en) | METHOD OF INVESTIGATING THE EFFECT OF AN ANGIONEGESIS HEMMER THROUGH INHIBITION BY INFRINGEMENT OF INTEGRIN EXPRESSION | |
| DE602004022266D1 (de) | Lkarzinoms der blase | |
| ES2077232T3 (es) | Procedimiento de determinacion de niveles del factor viii:ca de coagulacion sanguinea en distintas muestras. | |
| DE60114472D1 (de) | Verfahren zum auffinden von ozonverbrauchenden verbindungen | |
| DK1171578T3 (da) | Farmaceutisk præparat, som omfatter NKT-celler, der er aktiveret af PIM, og anvendelse heraf i terapi | |
| CR8973A (es) | Composicion farmaceutica en forma de una forma de dosificacion solida soluble en agua | |
| DE60130784D1 (de) | Verfahren zum überwachen des effekts von kathepsin-s-inhibitoren | |
| Kim et al. | The usefulness of Titmus test and distance stereoacuity using B-VAT (R) in intemittent exotropes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |